Azenta, Inc. (LON:0HQ1)
29.27
0.00 (0.00%)
At close: Sep 8, 2025
Azenta Revenue
Azenta had revenue of $143.94M USD in the quarter ending June 30, 2025, a decrease of -0.24%. This brings the company's revenue in the last twelve months to $668.82M, up 12.46% year-over-year. In the fiscal year ending September 30, 2024, Azenta had annual revenue of $656.32M, down -1.32%.
Revenue (ttm)
$668.82M
Revenue Growth
+12.46%
P/S Ratio
2.06
Revenue / Employee
$202.67K
Employees
3,300
Market Cap
1.00B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 656.32M | -8.75M | -1.32% |
Sep 30, 2023 | 665.07M | 109.57M | 19.73% |
Sep 30, 2022 | 555.50M | 41.80M | 8.14% |
Sep 30, 2021 | 513.70M | 125.17M | 32.21% |
Sep 30, 2020 | 388.54M | 54.36M | 16.27% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Azenta News
- 5 weeks ago - Azenta reaffirms 3%–5% organic growth and 300bps margin expansion for 2025 as operational turnaround advances - Seeking Alpha
- 5 weeks ago - Azenta, Inc. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Azenta (AZTA) Q3 EPS Jumps 36% - The Motley Fool
- 5 weeks ago - Azenta Non-GAAP EPS of $0.19 beats by $0.05, revenue of $144M misses by $5.81M - Seeking Alpha
- 5 weeks ago - Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance - PRNewsWire
- 6 weeks ago - Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology - PRNewsWire
- 6 weeks ago - Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care - PRNewsWire